-rank tests. Results: 60 female pts were included in this study. The median age was 59 years (24–78). 45 (75%) pts were postmenopausal, 44 (73%) ER+/PR+, 14 (23%) ER+/PR-, and 2 (3%) ER-PR-, 28 (47%) with only bone metastases, 19 (32%) with visceral and bone
Search Results
Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams
James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho
. Most patients with castration-recurrent or -resistant prostate cancer (CRPC) die of bone metastases and related complications. The recently approved radium-223 is the first bone-targeting agent to demonstrate a survival benefit in these patients
Rashmi Chugh
, which is implicated in many cancers. 29 , 30 Bisphosphonates reduce osteolytic bone metastases in many cancers, including breast cancer, myeloma, and prostate cancer. 31 These effects may result from bisphosphonates' effect on osteoclasts, angiogenesis
Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis, and Patrick Y. Wen
. Between 20% and 40% of patients with systemic cancer will develop brain metastases. 3 NOTE: This manuscript highlights only a portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System Cancers. Please refer
Douglas B. Johnson, Riyue Bao, Kristin K. Ancell, Anthony B. Daniels, Deborah Wallace, Jeffrey A. Sosman, and Jason J. Luke
metastases and 2 had prior therapies (see supplemental eAppendix 1 , available online with this article at JNCCN.org ). Of these 5 patients, 1 had a complete response (CR; ongoing at 25.5 months), and no partial responses were observed (response rate, 20
Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Úrsula Pérez-Ramírez, Javier Zamora, and the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis
Background Malignant or metastatic spinal cord compression of the thecal sac is a devastating medical emergency presented by 5% to 20% of patients with spinal metastases. 1 It can be caused by vertebral collapse, but is usually provoked by
Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz
better elucidate the distribution of age, sex, histologic subtype, and FG, in addition to assessing the rates of synchronous metastases in a large contemporary population-based cohort. We hypothesized that most patients harbored FG1–2 tumors, either the
Kathleen Harnden and Kimberly Blackwell
Bisphosphonates are an integral part of treatment for bone metastases in many malignancies, including breast cancer. Bone metastases can have devastating consequences, including severe pain, fractures, hypercalcemia, and spinal cord compression
Wen-Zhuo He, Wan-Ming Hu, Fang Wang, Yu-Ming Rong, Lin Yang, Qian-Kun Xie, Yuan-Zhong Yang, Chang Jiang, Hui-Juan Qiu, Jia-Bin Lu, Bei Zhang, Pei-Rong Ding, Xiao-Jun Xia, Jian-Yong Shao, and Liang-Ping Xia
, particularly genetic discordances between the primary and the metastatic sites. 3 – 6 Moreover, oxidative DNA damage and some chemokines were significantly higher in metastases than in primary tumors, 7 , 8 and the level of tumor-infiltrating lymphocytes and
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
patients with systemic cancer will develop brain metastases. 3 Principles of Management Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. Primary brain tumors range from
